These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16602235)

  • 1. New drugs: abatacept, sorafenib, and nelarabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2006; 46(2):300-3. PubMed ID: 16602235
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib and sunitinib.
    Kim A; Balis FM; Widemann BC
    Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis].
    Yasuoka Y; Goto A; Seriu T
    Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):87-94. PubMed ID: 21321458
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
    Hilger RA; Richly H; Grubert M; Kredtke S; Thyssen D; Eberhardt W; Hense J; Schuler M; Scheulen ME
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):61-4. PubMed ID: 19203541
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
    Bellini E; Pia A; Brizzi MP; Tampellini M; Torta M; Terzolo M; Dogliotti L; Berruti A
    Ann Oncol; 2011 Apr; 22(4):988-990. PubMed ID: 21321087
    [No Abstract]   [Full Text] [Related]  

  • 6. Can sorafenib cause hypothyroidism?
    Robinson SI; Hobday TJ; Sathananthan A; Morris JC; McWilliams RR
    J Chemother; 2007 Jun; 19(3):352-3. PubMed ID: 17594936
    [No Abstract]   [Full Text] [Related]  

  • 7. Keratoacanthomas associated with sorafenib therapy.
    Kong HH; Cowen EW; Azad NS; Dahut W; Gutierrez M; Turner ML
    J Am Acad Dermatol; 2007 Jan; 56(1):171-2. PubMed ID: 17190642
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib (BAY 43-9006): review of clinical development.
    Ng R; Chen EX
    Curr Clin Pharmacol; 2006 Sep; 1(3):223-8. PubMed ID: 18666747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
    Tolcher AW; Appleman LJ; Shapiro GI; Mita AC; Cihon F; Mazzu A; Sundaresan PR
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):751-64. PubMed ID: 20521052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
    Pécuchet N; Lebbe C; Mir O; Billemont B; Blanchet B; Franck N; Viguier M; Coriat R; Tod M; Avril MF; Goldwasser F
    Br J Cancer; 2012 Jul; 107(3):455-61. PubMed ID: 22767146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib-induced destructive thyroiditis.
    Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
    Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib: in advanced renal cancer.
    McKeage K; Wagstaff AJ
    Drugs; 2007; 67(3):475-83; discussion 484-5. PubMed ID: 17335301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib-induced eruption resembling pityriasis rubra pilaris.
    Paz C; Querfeld C; Shea CR
    J Am Acad Dermatol; 2011 Aug; 65(2):452-453. PubMed ID: 21763585
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 18. New drugs 07, part I.
    Hussar DA
    Nursing; 2007 Feb; 37(2):51-8; quiz 59-60. PubMed ID: 17273084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 20. BAY 43-9006: early clinical data in patients with advanced solid malignancies.
    Hotte SJ; Hirte HW
    Curr Pharm Des; 2002; 8(25):2249-53. PubMed ID: 12369852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.